Ryvu Therapeutics Second Quarter 2024 Earnings: zł1.40 loss per share (vs zł1.23 loss in 2Q 2023)

Ryvu Therapeutics (WSE:RVU) Second Quarter 2024 Results

Key Financial Results

• Revenue: zł23.0m (up 53% from 2Q 2023).
• Net loss: zł30.4m (loss widened by 6.7% from 2Q 2023).
• zł1.40 loss per share (further deteriorated from zł1.23 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ryvu Therapeutics Earnings Insights

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in Poland.

The company's shares are up 5.4% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Ryvu Therapeutics (1 shouldn't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.